Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer reported better than expected quarterly profits Tuesday behind cost cuts and growth in some non-Covid-related products in ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Pharma giant Merck on Tuesday announced in its earnings report that it would halt all shipments of HPV drug Gardasil to China ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...

Health-care companies fell amid mixed earnings and as a vaccine skeptic was set to take the reins of the U.S. health-care system. Merck shares fell after the Big Pharma company forecast 2025 sales of ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.